I usually skip BIO teams, but the story behind @brevis_zk made me pause.
The CEO Alan Li moving from biotech AI into zkML to lower prover costs is very clear to me. You can tell this came from trying things, not theory.
Seeing them go from 40% to 99% block coverage with less hardware stood out. The article reads like internal notes from tough problems, not a status post.
When builders share work like this, I’m more open to following the project, tbh 👑
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
I usually skip BIO teams, but the story behind @brevis_zk made me pause.
The CEO Alan Li moving from biotech AI into zkML to lower prover costs is very clear to me. You can tell this came from trying things, not theory.
Seeing them go from 40% to 99% block coverage with less hardware stood out. The article reads like internal notes from tough problems, not a status post.
When builders share work like this, I’m more open to following the project, tbh 👑